Roche's lampalizumab has met its Phase II primary endpoint in the MAHALO study, slowing the progression of geographic atrophy – an advanced form of dry age-related macular degeneration (dry AMD). The bad news: significant efficacy was only seen in patients dosed monthly (so patients won’t be able to dose once every other month to reduce the number of times they have to have needles stuck in their eyes). But the good news for Roche is that the drug seemed to perform twice as well in a biomarker-defined subset of patients.
Lapilizumab, a humanized antibody fragment that target an early step in the alternative complement pathway (factor D), appeared to reduce...
